Moneycontrol
Get App
Last Updated : Mar 19, 2019 03:46 PM IST | Source: Moneycontrol.com

Buy Ajanta Pharma; target of Rs 1080: Keynotes Financial Opiniery

Keynotes Financial Opiniery is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 1080 in its research report dated March 15, 2019.

Broker Research @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Keynotes Financial Opiniery's research report on Ajanta Pharma


Established in 1973 and headquartered in Mumbai India, we are committed to ‘Serve Health care needs worldwide.’ Ajanta pharma is a speciality pharmaceutical formulation company engaged in the development manufacture and marketing of quality finished dosages. The company is focused on the branded generics market in India, Asia and Africa, generics market in USA besides Institutional segment in Africa. With revenue being generated from a wide range of products and more than 30 countries, the company’s business is well diversified and de-risked. The company has six formulation manufacturing facilities (two are USFDA approved) and a state of the art Research & Development Centre spread over 1,00,000 sq.ft. Over 6500 employees are engaged worldwide to ensure efficient seamless business functioning. Ajanta Pharma is committed to providing access to quality education to underprivileged children to India.


Outlook


On the basis of Discount Cash Flow Valuation Method, we are recommending ‘Buy’ for the stock. Since the stock offers good opportunity, we initiate a ‘BUY’ signal on the stock with 12-month price target of Rs 1080/- share an upside of 20% from current levels.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Mar 19, 2019 03:46 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant